[Is reduction of hyperglycemia associated with a cardiovascular benefit?]

Fiche publication


Date publication

septembre 2018

Journal

Presse medicale (Paris, France : 1983)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr VERGES Bruno


Tous les auteurs :
Vergès B

Résumé

We have a large body of evidence showing that hyperglycemia is a cardiovascular risk factor and that its reduction decreases the risk for cardiovascular events. Indeed, epidemiological studies have clearly shown that hyperglycemia is a strong and independent factor for cardiovascular disease. In addition, we have many pathophysiological studies demonstrating the direct role of hyperglycemia in the development of atherosclerosis. Hyperglycemia, by stimulating protein kinase C, increases the production of pro-inflammatory cytokines, of adhesion molecules and of endothelin-1 and, by stimulating the polyol pathway, promotes the oxidative stress. Furthermore, chronic hyperglycemia leads to the accumulation of advanced glycation end-products that modify the structure of the arterial wall and, as a consequence, will increase the risk for the development of atherosclerosis. Moreover, prolonged intervention studies have shown that reduction of hyperglycemia is associated with a significant decrease in the risk for major cardiovascular events. Thus, hyperglycemia is a cardiovascular risk factor which is characterized by the fact that it induces profound modifications of the arterial wall and that it is necessary to correct hyperglycemia during enough time to obtain a cardiovascular benefit.

Mots clés

Atherosclerosis, blood, Cardiovascular Diseases, blood, Glycation End Products, Advanced, blood, Humans, Hyperglycemia, blood, Hypoglycemic Agents, therapeutic use, Oxidative Stress, physiology, Risk Factors

Référence

Presse Med. 2018 Sep 12;: